Wolverine stack dosage: reported doses and schedule
An unapproved recovery blend with no controlled human trial of the premixed product.
Also called: Wolverine blend, BPC/TB blend.
Community blends · Unapproved BPC-157 and TB-500 mixture; ratios and ingredient identities vary.
Typical reported dose: 0.5 mg each of BPC-157 and TB-500 once a day
- Equal parts, daily reports: 1 mg total: BPC-157 0.5 mg + TB-500 0.5 mg daily. once daily, under the skin. Reported by users, occasional report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
- Five dosing days, two off-days: 1 mg total on dosing days: BPC-157 0.5 mg + TB-500 0.5 mg. once daily on five days each week, under the skin. Reported by users, occasional report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Wolverine stack (BPC-157 + TB-500)
- KLOW blend: GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
- GLOW blend (GHK-Cu + BPC-157 + TB-500): An unapproved skin-and-recovery blend with no human combination study found.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting, FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.